Abbott reported second-quarter 2026 results with net sales of $12.593 billion and adjusted diluted EPS of $1.31 (GAAP diluted EPS $0.53). The company posted comparable sales growth of 4.8% for the quarter and raised its full-year 2026 adjusted diluted EPS guidance to $5.45–$5.60 while reaffirming comparable sales growth guidance of 6.5%–7.5%. Abbott returned $2.1 billion to shareholders in Q2 through dividends and share repurchases.

Financial Highlights

  • Revenue (Net Sales) — Q2 2026: $12,593 million (reported), up 13.0% vs Q2 2025.
  • Gross margin (as reported) — Q2 2026 gross margin reported: $6,610 million (see non-GAAP adjustments detailed in filing).
  • Operating earnings — Q2 2026: $1,693 million (operating earnings shown on condensed consolidated statement).
  • Net earnings — Q2 2026 GAAP net earnings: $928 million; Net earnings excluding specified items: $2,290 million.
  • Diluted EPS — Q2 2026 GAAP diluted EPS: $0.53; Diluted EPS excluding specified items: $1.31. Updated full-year 2026 adjusted diluted EPS guidance: $5.45 to $5.60.

Business Highlights

  • Comparable sales growth — Q2 2026 comparable sales growth of 4.8% companywide; reaffirmed full-year comparable sales guidance of 6.5%–7.5%.
  • Diagnostics momentum — Diagnostics reported sales of $3,092 million in Q2 2026 (reported) with comparable growth of 2.9%; Cancer Diagnostics (including Exact Sciences post-acquisition) showed mid-teens Cologuard growth and is presented as the Cancer Diagnostics business after the March 23, 2026 acquisition.
  • Medical Devices performance — Medical Devices reported sales of $5,853 million in Q2 2026 (reported) with comparable sales growth of 8.4%; growth led by Electrophysiology, Rhythm Management, Diabetes Care and Heart Failure franchises.
  • Nutrition segment — Worldwide Nutrition sales decreased 3.1% reported and 3.6% comparable in Q2, reflecting lower volumes and strategic pricing actions implemented in late 2025; sequential quarter improvement noted with a $127 million increase versus Q1 2026.
  • Strategic and product milestones — Completed enrollment in the TECTONIC U.S. pivotal trial for Coronary IVL; presented PFA and CSP late-breaking clinical data at HRS; secured CE Mark for Libre Duo (dual glucose-ketone sensor); submitted Amulet 360 LAA device to FDA; ACS reaffirmed Cologuard as a preferred CRC screening option for average-risk adults 45+.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.